Biodexa Pharmaceuticals (BDRX) Long-Term Investments (2013)
Biodexa Pharmaceuticals (BDRX) posted Long-Term Investments of $19428.9 for Q4 2013.
Biodexa Pharmaceuticals (BDRX) Long-Term Investments (2013) Analysis & Trends
Biodexa Pharmaceuticals has reported Long-Term Investments for 1 years, with the latest figure at $19428.9 in Q4 2013.
- Quarterly Long-Term Investments changed N/A year-over-year to $19428.9 in Q4 2013, while the trailing twelve-month figure through Dec 2013 was $19428.9 (changed N/A YoY) and the FY2013 annual result came in at $18778.0, changed N/A from the prior year.
- Long-Term Investments steadied at $19428.9 in Q4 2013 per BDRX's latest filing.
- Over five years, Long-Term Investments peaked at $19428.9 in Q4 2013 and troughed at $19428.9 in Q4 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.77 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.17 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 372.10 Mn |
| 10 | Biodexa Pharmaceuticals | 64,325.41 | -11.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2013 | 19,428.88 |